BiomX (NYSEMKT:PHGE) Trading Down 2%

BiomX Inc. (NYSEMKT:PHGE) fell 2% on Friday . The stock traded as low as $0.28 and last traded at $0.29. 69,414 shares were traded during trading, an increase of 1% from the average session volume of 68,601 shares. The stock had previously closed at $0.30.

BiomX Stock Down 2.0 %

The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The firm has a market cap of $16.01 million, a price-to-earnings ratio of -0.55 and a beta of 1.35. The firm has a 50-day moving average price of $0.32 and a two-hundred day moving average price of $0.31.

Institutional Investors Weigh In On BiomX

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC increased its position in BiomX by 208.6% during the fourth quarter. Millennium Management LLC now owns 270,848 shares of the company’s stock worth $51,000 after buying an additional 183,091 shares during the period. Susquehanna International Group LLP increased its position in BiomX by 372.4% during the first quarter. Susquehanna International Group LLP now owns 195,598 shares of the company’s stock worth $60,000 after buying an additional 154,189 shares during the period. Renaissance Technologies LLC increased its position in BiomX by 149.7% during the second quarter. Renaissance Technologies LLC now owns 195,495 shares of the company’s stock worth $70,000 after buying an additional 117,195 shares during the period. Finally, Jane Street Group LLC acquired a new position in BiomX during the first quarter worth approximately $48,000. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).